IP Library › Granted Patent US 12,364,774
Granted Patent B2
US 12,364,774 · App. 16/537,192 · Granted Jul 22, 2025

Nucleic acid molecules and uses thereof for non-viral gene therapy

Inventors: Tongyao Liu (Lexington, MA); Alexey Seregin (Westford, MA); Robert T. Peters (Needham, MA); Jiayun Liu (Wellesley, MA); Philip Zakas (Waltham, MA); Douglas Drager (Waltham, MA); Susannah Patarroyo-White (Waltham, MA)
Assignee: BIOVERATIV THERAPEUTICS INC.
A61K48/0058A61K9/0019A61K48/0016A61K48/0033A61K48/0066A61P7/04C07K14/755C12N7/00C12N15/86C12N2750/14143C12N2750/14171C12N2750/14343C12N2750/14371C12N2830/42C12N2830/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,774
App. No.
16/537,192
Granted
Jul 22, 2025
Kind
B2
Abstract

The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the target sequence encodes a miRNA and/or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and/or the second ITR is an ITR of a non-adeno-associated virus (AAV). The present disclosure also provides methods of treating a metabolic disorder of the liver in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide encoded thereby.

Claims (54)

1. A nucleic acid molecule comprising a first inverted terminal repeat (ITR) and a second ITR flanking a genetic cassette comprising a heterologous polynucleotide sequence, wherein the first ITR is a B19d135 5′ ITR consisting of the nucleotide sequence set forth in SEQ ID NO: 180 or the second ITR is a B19d135 3′ ITR consisting of the nucleotide sequence set forth in SEQ ID NO: 181.

2. The nucleic acid molecule of claim 1 , wherein the first ITR consists of the nucleotide sequence set forth in SEQ ID NO: 180 and the second ITR consists of the nucleotide sequence set forth in SEQ ID NO: 181.

3. The nucleic acid molecule of claim 1 , further comprising a tissue-specific promoter.

4. The nucleic acid molecule of claim 3 , wherein the promoter is a tristetraprolin (TTP) promoter.

5. The nucleic acid molecule of claim 1 , wherein the heterologous polynucleotide sequence further comprises a synthetic intronic sequence.

6. The nucleic acid molecule of claim 5 , wherein the intronic sequence comprises the nucleotide sequence of SEQ ID NO: 115 or 192.

7. The nucleic acid molecule of claim 1 , wherein the genetic cassette further comprises a post-transcriptional regulatory element.

8. The nucleic acid molecule of claim 7 , wherein the post-transcriptional regulatory element comprises a mutated woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), a microRNA binding site, a DNA nuclear targeting sequence, or any combination thereof.

9. The nucleic acid molecule of claim 8 , wherein the microRNA binding site comprises a binding site to miR142-3p.

10. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises from 5′ to 3′: the first ITR, the genetic cassette, and the second ITR; wherein the genetic cassette comprises a tissue-specific promoter sequence, an intronic sequence, the heterologous polynucleotide sequence, a post-transcriptional regulatory element, and a 3′UTR poly (A) tail sequence.

11. The nucleic acid molecule of claim 10 , wherein:

(a) the tissue specific promoter sequence comprises a TTP promoter;

(b) the intron is a synthetic intron;

(c) the post-transcriptional regulatory element comprises WPRE; and

(d) the 3′UTR poly (A) tail sequence comprises bGHpA.

12. The nucleic acid molecule of claim 1 , wherein the heterologous polynucleotide sequence encodes a factor VIII (FVIII) protein.

13. The nucleic acid molecule of claim 12 , wherein the FVIII protein comprises an amino acid sequence at least about 70% identical to the amino acid sequence of SEQ ID NO:109.

14. The nucleic acid molecule of claim 12 , wherein the heterologous polynucleotide sequence further encodes a protein heterologous moiety, wherein the heterologous moiety is an Fc region of an immunoglobulin constant domain.

15. The nucleic acid molecule of claim 14 , wherein the heterologous moiety is inserted into the FVIII protein immediately downstream of amino acid 745 corresponding to mature FVIII (SEQ ID NO:106).

16. The nucleic acid molecule of claim 12 , wherein the heterologous polynucleotide sequence encoding the FVIII protein comprises the nucleotide sequence of SEQ ID NO: 107 or the nucleotide sequence of SEQ ID NO: 71.

17. The nucleic acid molecule of claim 1 , wherein the heterologous polynucleotide sequence encodes a clotting factor.

18. The nucleic acid molecule of claim 1 , wherein the genetic cassette further comprises a 3′UTR poly (A) tail sequence.

19. The nucleic acid molecule of claim 18 , wherein the 3′UTR poly (A) tail sequence is selected from the group consisting of bGH poly (A), actin poly (A), and hemoglobin poly (A).

20. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is formulated with a delivery agent.

21. The nucleic acid molecule of claim 20 , wherein the delivery agent comprises a lipid nanoparticle.

22. A host cell comprising the nucleic acid molecule of claim 1 .

23. A pharmaceutical composition comprising the nucleic acid molecule of claim 1 , and a pharmaceutically acceptable excipient.

24. A nucleic acid molecule comprising a first ITR and a second ITR flanking a genetic cassette comprising a heterologous polynucleotide sequence, wherein the first ITR is a GPVd162 5′ ITR consisting of the nucleotide sequence set forth in SEQ ID NO: 183 or the second ITR is a GPVd162 3′ ITR consisting of the nucleotide sequence set forth in SEQ ID NO: 184.

25. The nucleic acid molecule of claim 24 , wherein the first ITR consists of the nucleotide sequence set forth in SEQ ID NO: 183 and the second ITR consists of the nucleotide sequence set forth in SEQ ID NO: 184.

26. The nucleic acid molecule of claim 24 , further comprising a tissue-specific promoter.

27. The nucleic acid molecule of claim 26 , wherein the promoter is a TTP promoter.

28. The nucleic acid molecule of claim 24 , wherein the heterologous polynucleotide sequence further comprises a synthetic intronic sequence.

29. The nucleic acid molecule of claim 28 , wherein the intronic sequence comprises the nucleotide sequence of SEQ ID NO: 115 or 192.

30. The nucleic acid molecule of claim 24 , wherein the heterologous polynucleotide sequence encodes a clotting factor.

31. The nucleic acid molecule of claim 24 , wherein the genetic cassette further comprises a post-transcriptional regulatory element.

32. The nucleic acid molecule of claim 31 , wherein the post-transcriptional regulatory element comprises a mutated woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), a microRNA binding site, a DNA nuclear targeting sequence, or any combination thereof.

33. The nucleic acid molecule of claim 32 , wherein the microRNA binding site comprises a binding site to miR142-3p.

34. The nucleic acid molecule of claim 24 , wherein the nucleic acid molecule comprises from 5′ to 3′: the first ITR, the genetic cassette, and the second ITR; wherein the genetic cassette comprises a tissue-specific promoter sequence, an intronic sequence, the heterologous polynucleotide sequence, a post-transcriptional regulatory element, and a 3′UTR poly (A) tail sequence.

35. The nucleic acid molecule of claim 34 , wherein:

(a) the tissue specific promoter sequence comprises a TTP promoter;

(b) the intron is a synthetic intron;

(c) the post-transcriptional regulatory element comprises WPRE; and

(d) the 3′UTR poly (A) tail sequence comprises bGHpA.

36. The nucleic acid molecule of claim 24 , wherein the genetic cassette further comprises a 3′UTR poly (A) tail sequence.

37. The nucleic acid molecule of claim 36 , wherein the 3′UTR poly (A) tail sequence is selected from the group consisting of bGH poly (A), actin poly (A), and hemoglobin poly (A).

38. The nucleic acid molecule of claim 24 , wherein the heterologous polynucleotide sequence encodes a FVIII protein.

39. The nucleic acid molecule of claim 38 , wherein the FVIII protein comprises an amino acid sequence at least about 70% identical to the amino acid sequence of SEQ ID NO:109.

40. The nucleic acid molecule of claim 38 , wherein the heterologous polynucleotide sequence further encodes a protein heterologous moiety, wherein the heterologous moiety is an Fc region of an immunoglobulin constant domain.

41. The nucleic acid molecule of claim 40 , wherein the heterologous moiety is inserted into the FVIII protein immediately downstream of amino acid 745 corresponding to mature FVIII (SEQ ID NO:106).

42. The nucleic acid molecule of claim 38 , wherein the heterologous polynucleotide sequence encoding the FVIII protein comprises the nucleotide sequence of SEQ ID NO: 107 or the nucleotide sequence of SEQ ID NO: 71.

43. The nucleic acid molecule of claim 24 , wherein the nucleic acid molecule is formulated with a delivery agent.

44. The nucleic acid molecule of claim 43 , wherein the delivery agent comprises a lipid nanoparticle.

45. A host cell comprising the nucleic acid molecule of claim 24 .

46. A pharmaceutical composition comprising the nucleic acid molecule of claim 24 , and a pharmaceutically acceptable excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2025
From: LIU, TONGYAO; SEREGIN, ALEXEY; PETERS, ROBERT T.; LIU, JIAYUN
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 071456/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2021
From: DRAGER, DOUGLAS; PATARROYO-WHITE, SUSANNAH; ZAKAS, PHILIP
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 055073/0609 →
Continuity (2)
Provisional Application 62716826 · Aug 9, 2018
Related Publication 20200069817A1 · Mar 5, 2020
References Cited (400)
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Kary · 1987 [cited by applicant]
US 4770999A · Kaufman et al. · 1988 [cited by applicant]
US 4800159A · Mullis et al. · 1989 [cited by applicant]
US 4868112A · Toole, Jr. · 1989 [cited by applicant]
US 4965188A · Mullis et al. · 1990 [cited by applicant]
US 5112950A · Meulien et al. · 1992 [cited by applicant]
US 5171844A · Van Ooyen et al. · 1992 [cited by applicant]
US 5304489A · Rosen · 1994 [cited by applicant]
US 5543502A · Nordfang et al. · 1996 [cited by applicant]
US 5595886A · Chapman et al. · 1997 [cited by applicant]
US 5610278A · Nordfang et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5658570A · Newman et al. · 1997 [cited by applicant]
US 5712122A · Boime et al. · 1998 [cited by applicant]
US 5736137A · Andersopn et al. · 1998 [cited by applicant]
US 5739277A · Presta et al. · 1998 [cited by applicant]
US 5741957A · Deboer et al. · 1998 [cited by applicant]
US 5789203A · Chapman et al. · 1998 [cited by applicant]
US 5834250A · Wells et al. · 1998 [cited by applicant]
US 5849992A · Meade et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5972885A · Spira et al. · 1999 [cited by applicant]
US 6030613A · Blumberg et al. · 2000 [cited by applicant]
US 6033885A · Latta et al. · 2000 [cited by applicant]
US 6048720A · Dalborg et al. · 2000 [cited by applicant]
US 6060447A · Chapman et al. · 2000 [cited by applicant]
US 6086875A · Blumberg et al. · 2000 [cited by applicant]
US 6096871A · Presta et al. · 2000 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6159730A · Reff · 2000 [cited by applicant]
US 6193980B1 · Efstathiou et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6228620B1 · Chapman et al. · 2001 [cited by applicant]
US 6242195B1 · Idusogie et al. · 2001 [cited by applicant]
US 6251632B1 · Lillicrap et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6291214B1 · Richards et al. · 2001 [cited by applicant]
US 6316226B1 · Van Ooyen et al. · 2001 [cited by applicant]
US 6346513B1 · Van Ooyen et al. · 2002 [cited by applicant]
US 6413777B1 · Reff et al. · 2002 [cited by applicant]
US 6458563B1 · Lollar · 2002 [cited by applicant]
US 6485726B1 · Blumberg et al. · 2002 [cited by applicant]
US 6491907B1 · Rabinowitz · 2002 [cited by applicant]
US 6528624B1 · Idusogie et al. · 2003 [cited by applicant]
US 6538124B1 · Idusogie et al. · 2003 [cited by applicant]
US 6696245B2 · Winter et al. · 2004 [cited by applicant]
US 6723551B2 · Kotin et al. · 2004 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6808905B2 · McArthur et al. · 2004 [cited by applicant]
US 6821505B2 · Ward · 2004 [cited by applicant]
US 6998253B1 · Presta et al. · 2006 [cited by applicant]
US 7041635B2 · Kim et al. · 2006 [cited by applicant]
US 7083784B2 · Dall'Acqua et al. · 2006 [cited by applicant]
US 7179903B2 · McArthur et al. · 2007 [cited by applicant]
US 7271002B2 · Kotin et al. · 2007 [cited by applicant]
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7404956B2 · Peters et al. · 2008 [cited by applicant]
US 7598071B2 · Brown et al. · 2009 [cited by applicant]
US 7700734B2 · Lin et al. · 2010 [cited by applicant]
US 7745179B2 · McArthur et al. · 2010 [cited by applicant]
US 7939632B2 · Metzner et al. · 2011 [cited by applicant]
US 8071751B2 · Delwart et al. · 2011 [cited by applicant]
US 8110350B2 · Allander et al. · 2012 [cited by applicant]
US 8945918B2 · Chen et al. · 2015 [cited by applicant]
US 9062098B2 · Allander et al. · 2015 [cited by applicant]
US 9115373B2 · Hermens et al. · 2015 [cited by applicant]
US 9186381B2 · Zender et al. · 2015 [cited by applicant]
US 9212374B2 · Roy et al. · 2015 [cited by applicant]
US 9828587B2 · Yan et al. · 2017 [cited by applicant]
US 9856468B2 · Salas et al. · 2018 [cited by applicant]
US 9879279B2 · Chen · 2018 [cited by applicant]
US 9890365B2 · Wang · 2018 [cited by examiner]
US 9943611B2 · Balazs et al. · 2018 [cited by applicant]
US 10793835B2 · Yan et al. · 2020 [cited by applicant]
US 11066679B2 · Kotin et al. · 2021 [cited by applicant]
US 11103597B2 · Gray et al. · 2021 [cited by applicant]
US 11142775B2 · Yan et al. · 2021 [cited by applicant]
US 11634742B2 · De Beer et al. · 2023 [cited by applicant]
US 12168776B2 · Liu et al. · 2024 [cited by applicant]
US 20030069395A1 · Sato et al. · 2003 [cited by applicant]
US 20030235536A1 · Blumberg et al. · 2003 [cited by applicant]
US 20060008469A1 · Brown et al. · 2006 [cited by applicant]
US 20070231329A1 · Lazar et al. · 2007 [cited by applicant]
US 20070237765A1 · Lazar et al. · 2007 [cited by applicant]
US 20070237766A1 · Lazar et al. · 2007 [cited by applicant]
US 20070237767A1 · Lazar et al. · 2007 [cited by applicant]
US 20070243188A1 · Lazar et al. · 2007 [cited by applicant]
US 20070248603A1 · Lazar et al. · 2007 [cited by applicant]
US 20070253936A1 · Kay et al. · 2007 [cited by applicant]
US 20070286859A1 · Lazar et al. · 2007 [cited by applicant]
US 20080004206A1 · Rosen et al. · 2008 [cited by applicant]
US 20080057056A1 · Lazar et al. · 2008 [cited by applicant]
US 20080153751A1 · Rosen et al. · 2008 [cited by applicant]
US 20080161243A1 · Rosen et al. · 2008 [cited by applicant]
US 20080194481A1 · Rosen et al. · 2008 [cited by applicant]
US 20080213233A1 · Wang · 2008 [cited by examiner]
US 20080260738A1 · Moore et al. · 2008 [cited by applicant]
US 20080261877A1 · Ballance et al. · 2008 [cited by applicant]
US 20090087411A1 · Fares et al. · 2009 [cited by applicant]
US 20100136514A1 · Brown · 2010 [cited by examiner]
US 20100239554A1 · Schellenberger et al. · 2010 [cited by applicant]
US 20100292130A1 · Skerra et al. · 2010 [cited by applicant]
US 20100323956A1 · Schellenberger et al. · 2010 [cited by applicant]
US 20110046060A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110046061A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110077199A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110172146A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110190166A1 · Wong et al. · 2011 [cited by applicant]
US 20130109742A1 · Hewitt et al. · 2013 [cited by applicant]
US 20140107186A1 · Garcia · 2014 [cited by examiner]
US 20140271551A1 · Hirsch et al. · 2014 [cited by applicant]
US 20140308280A1 · Maloney et al. · 2014 [cited by applicant]
US 20140370035A1 · Jiang et al. · 2014 [cited by applicant]
US 20150023959A1 · Chhabra et al. · 2015 [cited by applicant]
US 20150111955A1 · High et al. · 2015 [cited by applicant]
US 20150158929A1 · Schellenberger et al. · 2015 [cited by applicant]
US 20160102297A1 · Hewitt · 2016 [cited by examiner]
US 20160229904A1 · Xiao et al. · 2016 [cited by applicant]
US 20160296607A1 · Jiang · 2016 [cited by examiner]
US 20160311885A1 · Peters · 2016 [cited by examiner]
US 20170021037A1 · Wang et al. · 2017 [cited by applicant]
US 20170081392A1 · Wilson et al. · 2017 [cited by applicant]
US 20170130245A1 · Kotin · 2017 [cited by examiner]
US 20170356009A1 · Lu et al. · 2017 [cited by applicant]
US 20170362608A1 · McLaughlin et al. · 2017 [cited by applicant]
US 20190048362A1 · Kyostio-Moore et al. · 2019 [cited by applicant]
US 20190185543A1 · Tan et al. · 2019 [cited by applicant]
US 20190203229A1 · Engelhardt et al. · 2019 [cited by applicant]
US 20200069817A1 · Liu et al. · 2020 [cited by applicant]
US 20200224220A1 · Finer et al. · 2020 [cited by applicant]
US 20200283794A1 · Kotin et al. · 2020 [cited by applicant]
US 20210010028A1 · Horowitz et al. · 2021 [cited by applicant]
US 20210163986A1 · Seregin et al. · 2021 [cited by applicant]
US 20220042040A1 · Grabherr et al. · 2022 [cited by applicant]
US 20220090130A1 · Maghodia et al. · 2022 [cited by applicant]
US 20220175970A1 · Kerr et al. · 2022 [cited by applicant]
US 20220243201A1 · Maghodia et al. · 2022 [cited by applicant]
US 20220356490A1 · Liu et al. · 2022 [cited by applicant]
US 20230063208A1 · Ceruti et al. · 2023 [cited by applicant]
US 20230084036A1 · Maghodia et al. · 2023 [cited by applicant]
US 20230091932A1 · Maghodia et al. · 2023 [cited by applicant]
US 20240294940A1 · Maghodia et al. · 2024 [cited by applicant]
US 20240350671A1 · Maghodia et al. · 2024 [cited by applicant]
CN 101124328A · 2008 [cited by applicant]
CN 103215308A · 2013 [cited by applicant]
CN 107531774A · 2018 [cited by applicant]
CN 111247251A · 2020 [cited by applicant]
EP 0295597A2 · 1988 [cited by applicant]
EP 1395293A1 · 2004 [cited by applicant]
EP 1572893B1 · 2009 [cited by applicant]
EP 2292781A1 · 2011 [cited by applicant]
EP 2061891B1 · 2012 [cited by applicant]
EP 2508607A1 · 2012 [cited by applicant]
EP 2195439B1 · 2013 [cited by applicant]
EP 2698163 · 2014 [cited by examiner]
EP 2698163A1 · 2014 [cited by applicant]
EP 3230441A4 · 2018 [cited by applicant]
EP 3294309A4 · 2019 [cited by applicant]
EP 3476860A1 · 2019 [cited by applicant]
EP 2914731B1 · 2019 [cited by applicant]
EP 3665289A1 · 2020 [cited by applicant]
EP 3722434A1 · 2020 [cited by applicant]
EP 3678710A4 · 2021 [cited by applicant]
EP 3833766A1 · 2021 [cited by applicant]
EP 3423110B1 · 2021 [cited by applicant]
EP 3877528A1 · 2021 [cited by applicant]
EP 3914717A1 · 2021 [cited by applicant]
EP 4199971A1 · 2023 [cited by applicant]
EP 4392444A1 · 2024 [cited by applicant]
EP 4392445A1 · 2024 [cited by applicant]
EP 4392566A2 · 2024 [cited by applicant]
JP 2002527493A · 2002 [cited by applicant]
JP 2011067212A · 2011 [cited by applicant]
JP 2014511180A · 2014 [cited by applicant]
JP 2014511690A · 2014 [cited by applicant]
RU 2569183C2 · 2015 [cited by applicant]
TW 201629225A · 2016 [cited by applicant]
WO WO1987004187A1 · 1987 [cited by applicant]
WO WO1988000831A1 · 1988 [cited by applicant]
WO WO1988007089A1 · 1988 [cited by applicant]
WO WO1991009122A1 · 1991 [cited by applicant]
WO WO1994028157A1 · 1994 [cited by applicant]
WO WO1995009923A1 · 1995 [cited by applicant]
WO WO1995023867A1 · 1995 [cited by applicant]
WO WO1996014339A1 · 1996 [cited by applicant]
WO WO1998005787A1 · 1998 [cited by applicant]
WO WO1998023289A1 · 1998 [cited by applicant]
WO WO1999051642A1 · 1999 [cited by applicant]
WO WO1999058572A1 · 1999 [cited by applicant]
WO WO2000005355A1 · 2000 [cited by applicant]
WO WO2000009560A2 · 2000 [cited by applicant]
WO WO2000023116A1 · 2000 [cited by applicant]
WO WO2000028004A1 · 2000 [cited by applicant]
WO WO2000032767A1 · 2000 [cited by applicant]
WO WO2000042072A2 · 2000 [cited by applicant]
WO WO2001075092A2 · 2001 [cited by applicant]
WO WO2002044215A2 · 2002 [cited by applicant]
WO WO2002060919A2 · 2002 [cited by applicant]
WO WO2002040544A3 · 2002 [cited by applicant]
WO WO2002092134A1 · 2002 [cited by applicant]
WO WO2003020764A2 · 2003 [cited by applicant]
WO WO2003042361A2 · 2003 [cited by applicant]
WO WO2003074569A2 · 2003 [cited by applicant]
WO WO2003077834A2 · 2003 [cited by applicant]
WO WO2004016750A2 · 2004 [cited by applicant]
WO WO2004029207A2 · 2004 [cited by applicant]
WO WO2004035752A2 · 2004 [cited by applicant]
WO WO2004044859A1 · 2004 [cited by applicant]
WO WO2004063351A2 · 2004 [cited by applicant]
WO WO2004074455A2 · 2004 [cited by applicant]
WO WO2004094642A2 · 2004 [cited by applicant]
WO WO2004099249A2 · 2004 [cited by applicant]
WO WO2005040217A2 · 2005 [cited by applicant]
WO WO2005070963A1 · 2005 [cited by applicant]
WO WO2005077981A2 · 2005 [cited by applicant]
WO WO2005085456A1 · 2005 [cited by applicant]
WO WO2005092925A2 · 2005 [cited by applicant]
WO WO2007057062A1 · 2005 [cited by applicant]
WO WO2005123780A2 · 2005 [cited by applicant]
WO WO2006019447A1 · 2006 [cited by applicant]
WO WO2006033756A · 2006 [cited by applicant]
WO WO2006047350A2 · 2006 [cited by applicant]
WO WO2006085967A2 · 2006 [cited by applicant]
WO WO2007000668A2 · 2007 [cited by applicant]
WO WO2007021494A2 · 2007 [cited by applicant]
WO WO2007149406A2 · 2007 [cited by applicant]
WO WO2008012543A1 · 2008 [cited by applicant]
WO WO2008016391A2 · 2008 [cited by applicant]
WO WO2008024998A2 · 2008 [cited by applicant]
WO WO2008033413A2 · 2008 [cited by applicant]
WO WO2008118507A2 · 2008 [cited by applicant]
WO WO2008141400A1 · 2008 [cited by applicant]
WO WO2008143954A2 · 2008 [cited by applicant]
WO WO2008155134A1 · 2008 [cited by applicant]
WO WO2009038462A1 · 2009 [cited by applicant]
WO WO2009051717A2 · 2009 [cited by applicant]
WO WO2009058322A1 · 2009 [cited by applicant]
WO WO2009130198A2 · 2009 [cited by applicant]
WO WO2009137254A2 · 2009 [cited by applicant]
WO WO2009140015A2 · 2009 [cited by applicant]
WO WO2009146210A2 · 2009 [cited by applicant]
WO WO2010055413A1 · 2010 [cited by applicant]
WO WO2010091122A1 · 2010 [cited by applicant]
WO WO2010125471A2 · 2010 [cited by applicant]
WO WO2010140148A1 · 2010 [cited by applicant]
WO WO2010144502A2 · 2010 [cited by applicant]
WO WO2010144508A1 · 2010 [cited by applicant]
WO WO2011020710A2 · 2011 [cited by applicant]
WO WO2011028228A1 · 2011 [cited by applicant]
WO WO2011028229A1 · 2011 [cited by applicant]
WO WO2011028344A2 · 2011 [cited by applicant]
WO WO2011088081A1 · 2011 [cited by applicant]
WO WO2011100330A2 · 2011 [cited by applicant]
WO WO2011112090A2 · 2011 [cited by applicant]
WO WO2012006624A2 · 2012 [cited by applicant]
WO WO2012006635A1 · 2012 [cited by applicant]
WO WO2012115980A1 · 2012 [cited by applicant]
WO WO2012136859A1 · 2012 [cited by applicant]
WO WO2013123457A1 · 2013 [cited by applicant]
WO WO2014011819A2 · 2014 [cited by applicant]
WO WO2014070949A1 · 2014 [cited by applicant]
WO WO2014127215A1 · 2014 [cited by applicant]
WO WO2014143932A1 · 2014 [cited by applicant]
WO WO2014168953A1 · 2014 [cited by applicant]
WO WO2015023891A2 · 2015 [cited by applicant]
WO WO2015038625A1 · 2015 [cited by applicant]
WO WO2015106052A1 · 2015 [cited by applicant]
WO WO2015191508A1 · 2015 [cited by applicant]
WO WO2016004113A1 · 2016 [cited by applicant]
WO WO2016081927A2 · 2016 [cited by applicant]
WO WO2016094783A1 · 2016 [cited by applicant]
WO WO2016127057A1 · 2016 [cited by applicant]
WO WO2016134338A1 · 2016 [cited by applicant]
WO WO2016183422A1 · 2016 [cited by applicant]
WO WO2017075619A1 · 2017 [cited by applicant]
WO WO2017136358A1 · 2017 [cited by applicant]
WO WO2017152149A1 · 2017 [cited by applicant]
WO WO2017205739A1 · 2017 [cited by applicant]
WO WO2018024998A1 · 2018 [cited by applicant]
WO WO2018132747A1 · 2018 [cited by applicant]
WO WO2019014623A1 · 2019 [cited by applicant]
WO WO2008016391A1 · 2019 [cited by applicant]
WO WO2019032102A1 · 2019 [cited by applicant]
WO WO2019032898A1 · 2019 [cited by applicant]
WO WO2019051255A1 · 2019 [cited by applicant]
WO WO2019051289A1 · 2019 [cited by applicant]
WO WO2019067766A1 · 2019 [cited by applicant]
WO WO2019113310A1 · 2019 [cited by applicant]
WO WO2019143885A1 · 2019 [cited by applicant]
WO WO2019161059A1 · 2019 [cited by applicant]
WO WO2019165050A1 · 2019 [cited by applicant]
WO WO2019169232A1 · 2019 [cited by applicant]
WO WO2019169233A1 · 2019 [cited by applicant]
WO WO2019173434A1 · 2019 [cited by applicant]
WO WO2019246544A3 · 2019 [cited by applicant]
WO WO2020033863A1 · 2020 [cited by applicant]
WO WO2020069429A1 · 2020 [cited by applicant]
WO WO2020077250A1 · 2020 [cited by applicant]
WO WO2020097417A1 · 2020 [cited by applicant]
WO WO2020154645A1 · 2020 [cited by applicant]
WO WO2020161168A1 · 2020 [cited by applicant]
WO WO2020168222A1 · 2020 [cited by applicant]
WO WO2020181182A1 · 2020 [cited by applicant]
WO WO2020186207A2 · 2020 [cited by applicant]
WO WO2020208379A1 · 2020 [cited by applicant]
WO WO2020225405A1 · 2020 [cited by applicant]
WO WO2020257590A1 · 2020 [cited by applicant]
WO WO2021011840A1 · 2021 [cited by applicant]
WO WO2021216975A1 · 2021 [cited by applicant]
WO WO2022046665A1 · 2022 [cited by applicant]
WO WO2023028440A2 · 2023 [cited by applicant]
WO WO2023028441A1 · 2023 [cited by applicant]
WO WO2023028455A1 · 2023 [cited by applicant]
Ward et al, Codon optimization of human factor VIII cDNAs leads to high-level expression, Blood, 2011, pp. 798-807. [cited by examiner]
Nguyen et al, Evaluation of Gene Promoters For Liver Expression By Hydrodynamic Gene Transfer, J Surg Res. Jul. 2008 ; 148(1): 60-66. [cited by examiner]
Bzymek et al., “Evidence for Two Mechanisms of Palindrome-Stimulated Deletion in [cited by applicant]
Cotter et al., “The induction of Inflammation by Adenovirus Vectors used for Gene Therapy”, Frontiers in Bioscience vol. 10, May 1, 2005, pp. 10-18-1105. [cited by applicant]
Doherty et al., “ [cited by applicant]
Dong et al., “Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus”, Human Gene Therapy vol. 7, pp. 2101-2112, Nov. 10, 1996. [cited by applicant]
Gottlieb et al., “In vitro Excision of Adeno-Associated Virus DNA from Recombinant Plasmids: Isolation of an Enzyme Fraction from HeLa Cells That Cleaves DNA at Poly(G) Sequences”, Molecular and Cellular Biology, vol. 6… [cited by applicant]
Kulkarni et al., “Interaction Between the sbcC Gene of [cited by applicant]
Leach, “Long DNA Palindromes, Cruciform Structures, Genetic Instability and Secondary Structure Repair”, BioEssays, vol. 16, No. 12, Dec. 1994, pp. 893-900. [cited by applicant]
Li et al., “Production and characterization of Novel Recombinant Adeno-Associated Virus Replicative-Form Genomes: A Eukaryotic Source of DNA for Gene Transfer”, PLoS ONE vol. 8, Issue 8, e69879, Aug. 2013. [cited by applicant]
Lilley, David M.J., “In vivo consequences of Plasmid Topology”, Nature, vol. 292, Jul. 23, 1981, pp. 380-382. [cited by applicant]
McLaughlin et al., “Adeno-Associated Virus General Transduction Vectors: Analysis of Proviral Structures”, Journal of Virology, vol. 62, No. 6, Jun. 1988, pp. 1963-1973. [cited by applicant]
Naso et al., “Adeno-Associated Virus (AAV) as a Bector for Gene Therapy”, BioDrugs, vol. 31, 2017, pp. 317-334. [cited by applicant]
Ni et al., “Virus-Inspired Nucleic Acid Delivery System: Linking Virus and Viral Mimicry”, Advanced Drug Delivery Reviews vol. 106, 2016, pp. 3-26. [cited by applicant]
Samulski et al., “Rescue of Adeno-Associated Virus from Recombinant Plasmids: Gene Correction Within the Terminal Repeats of AAV”, Cell, vol. 33, Issue 1, May 1983, pp. 135-143. [cited by applicant]
Samulski et al., “A Recombinant Plasmid from Which an Infectious Adeno-Associated Virus Genome Can Be Excised In Vitro and Its Use to Study Viral Replication”, Journal of Virology, vol. 61, No. 10, Oct. 1987, pp. 3096-3… [cited by applicant]
Samulski et al., “Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression”, Journal of Virology, vol. 63, No. 9, Sep. 1989, pp. 3822-3828. [cited by applicant]
Senapathy et al., “Molecular Cloning of Adeno-Associated Virus Variant Genomes and Generation of Infectious Virus by Recombination in Mammalian Cells”, Journal of Biological Chemistry, vol. 259, No. 7, Apr. 10, 1984, pp… [cited by applicant]
Zhou et al., “Deletion of the B-B′ and C-C′ regions of inverted terminal repeats reduces rAAV productivity but increases transgene expression”, Scientific Reports 7: 5432. [cited by applicant]
Luo et al. “Human parvovirus B19: a mechanistic overview of infection and DNA replication”, Future Virology, vol. 10, No. 2, Feb. 1, 2015, pp. 155-167, XP055637456, UK. [cited by applicant]
Manaresi et al. “A Parvovirus B19 synthetic genome: sequence features and functional competence”, Virology, vol. 508, May 10, 2017, pp. 54-62, XP085068336, Amsterdam, NL. [cited by applicant]
Wang et al. “Sequencing and generation of an infectious clone of the pathogenic goose parvovirus strain LH”, Archives of Virology, vol. 160, No. 3, Jan. 7, 2015, pp. 711-718, XP035455223, AT. [cited by applicant]
Connelly et al. “The sbcC and sbcD genes of [cited by applicant]
Armour et al., “Recombinant Human IgG Molecules Lacking Fc Gamma Receptor I Binding And Monocyte Triggering Activities”, European Journal of Immunology, vol. 29, No. 8, pp. 2613-2624, Aug. 1999. [cited by applicant]
Babkin et al., “A study of the human bocavirus replicative genome structures”, Virus Research, Oct. 31, 2014, 195: 196-202. [cited by applicant]
Baldassarre et al., “Production of Transgenic Goats By Pronuclear Microinjection Of In Vitro Produced Zygotes Derived From Oocytes Recovered By Laparoscopy”, Theriogenology, vol. 59, Issues 3-4, pp. 831-839, Feb. 2003. [cited by applicant]
Beerli et al. (2002) “Engineering polydactyl zinc-finger transcription factors”, Nature Biotechnol., 20: 135-141. [cited by applicant]
Behrman et al., “A CHOP-Regulated MicroRNA Controls Rhodopsin Expression”, Journal of Cell Biology, 2011, vol. 192, No. 6, pp. 919-927. [cited by applicant]
Benhar et al., “Cloning, Expression and Characterization Of The Fv Fragments Of The Anti-Carbohydrate mAbs BI and B5 As Single-Chain Immunotoxins”, Protein Engineering, Design and Selection, vol. 7, No. 12, pp. 1509-151… [cited by applicant]
Bril et al. (2006) “Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg [cited by applicant]
Brinster et al., “Expression of A Microinjected Immunoglobulin Gene In The Spleen Of Transgenic Mice”, Nature, vol. 306, No. 5941, pp. 332-336, 1983. [cited by applicant]
Brinster et al., “Factors Affecting the Efficiency of Introducing Foreign DNA Into Mice by Microinjecting Eggs”, Proceedings of the National Academy of Sciences of the United States of America, vol. 82, No. 13, pp. 4438… [cited by applicant]
Brown et al., “Production of Recombinant H1 Parvovirus Stocks Devoid of Replication-Competent Viruses”, Human Gene Therapy, vol. 13, No. 18, pp. 2135-2145, Dec. 10, 2002. [cited by applicant]
Burmeister et al., “Crystal Structure of the Complex of Rat Neonatal Fc Receptor with Fc”, Nature, Nov. 24, 1994, vol. 372, No. 6504, pp. 379-383. [cited by applicant]
Cameron et al., “The Canine Factor VIII cDNA and 5′ Flanking Sequence”, Journal of Thrombosis and Haemostasis, Feb. 1998, vol. 79, No. 2, pp. 317-322. [cited by applicant]
Capon et al. (1989) “Designing CD4 immunoadhesins for AIDS therapy,” Nature, 337, 525-531. [cited by applicant]
Chen et al. (2005) “MicroRNAs as regulators of mammalian hematopoiesis,” Seminars in Immunology, 17:155-165. [cited by applicant]
Chiorini et al. (1997) “Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles”, J. Vir., 71: 6823-6833. [cited by applicant]
Chiorini et al. (1999) “Cloning and Characterization of Adeno-Associated Virus Type 5”, J. Vir. 73: 1309-1319. [cited by applicant]
Cho et al., (2015) “DNA repair: ends with alternative endings”, Nature 518, 174-176. [cited by applicant]
Choo et al. (2000) “Advances in zinc finger engineering”, Curr. Opin. Struct. Biol. 10(4): 411-416. [cited by applicant]
Choo et al., “Molecular Cloning of The Gene for Human Anti-Haemophilic Factor IX”, Nature, 1982, vol. 299, No. 5879, pp. 178-180. [cited by applicant]
Connelly et al., “The sbcC and sbcD genes of [cited by applicant]
Costa et al. (1986) “Transcriptional Control of the Mouse Prealbumin (Transthyretin) Gene: Both Promoter Sequences and a Distinct Enhancer Are Cell Specific,” Molecular and Cellular Biology, 6(12):4697-4708. [cited by applicant]
Cutler et al., “The Identification and Classification Of 41 Novel Mutations In The Factor VIII Gene (F8c)”, Human Mutation, Mar. 2002, vol. 19, No. 3, pp. 274-278. [cited by applicant]
Dalkara et al. (2013) “In Vivo-Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous”, Sci. Transl. Med. 5(189): 189ra76. [cited by applicant]
Deng et al., “Site-Directed Mutagenesis of Virtually any Plasmid by Eliminating a Unique Site”, Analytical Biochemistry, Jan. 1, 1992, vol. 200, Issue 1, pp. 81-88. [cited by applicant]
Dennis et al. (2002) “Albumin binding as a general strategy for improving the pharmacokinetics of proteins,” The Journal of Biological Chemistry, 277(38):35035-35043. [cited by applicant]
Dirren et al., “SOD1 Silencing in Motoneurons or Glia Rescues Neuromuscular Function in ALS Mice”, Annals of Clinical and Translational Neurology, Feb. 2015, vol. 2, No. 2, pp. 167-184. [cited by applicant]
Eaton et al., “Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule”, Biochemistry, Dec. 1986, vol. 25, No. 26, pp. 8343-8347. [cited by applicant]
Ellman et al. (1991) “Biosynthetic Method for Introducing Unnatural Amino Acids Site-Specifically into Proteins,” Methods In Enzymology, 202 (15): 301-336. [cited by applicant]
Esvelt et al. (Nov. 2013) “Orthogonal Cas9 proteins for RNA-guided gene regulation and editing”, Nat Methods., 10(11): 1116-1121. [cited by applicant]
Evers et al., “AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model”, Molecular Therapy, Sep. 5, 2018, vol. 26, Issue 9, pp. 2163-21… [cited by applicant]
Fair et al., “Human Hepatoma Cells Secrete Single Chain Factor X, Prothrombin, And Antithrombin III”, Blood, 1984, vol. 64, No. 1, pp. 194-204. [cited by applicant]
Fallaux et al. (1996) “The Human Clotting Factor VIII cDNA Contains an Autonomously Replicating Sequence Consensus- and Matrix Attachment Region-Like Sequence That Binds a Nuclear Factor, Represses Heterologous Gene Exp… [cited by applicant]
Figueiredo et al., “Cis-Acting Elements and Transcription Factors Involved in the Promoter Activity of The Human Factor VIII Gene”, Journal of Biological Chemistry, May 19, 1995, vol. 270, No. 20, pp. 11828-11838. [cited by applicant]
Friend et al. (1999) “Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection,” Transplantation, 68 (11): 1632-1637. [cited by applicant]
Gao et al., “Clades of Adeno-Associated Viruses are Widely Disseminated in Human Tissues”, Journal of Virology, Jun. 15, 2004, vol. 78, No. 12, pp. 6381-6388. [cited by applicant]
Genbank, “”, GenBank Accession No. U25749.1, Dec. 12, 1995, Retrieved From: https://www.ncbi.nlm.nih.gov/nuccore/U25749.1. [cited by applicant]
Genbank, “Adeno-associated virus-2, complete genome”, GenBank Accession No. NC_001401.2, Aug. 13, 2019, Retrieved From: https://www.ncbi.nlm.nih.gov/nuccore/NC_001401.2. [cited by applicant]
Genbank, “Adeno-associated virus 2, complete genome”, GenBank Accession No. AF043303.1, May 20, 2010, Retrieved From: <<http://www.ncbi.nlm.nih.gov/nuccore/AF043303>>. [cited by applicant]
Genbank, “Adeno-associated virus 5 DNA binding trs helicase (Rep22) and capsid protein (VP1) genes, complete cds”, GenBank Accession No. AF085716.1, Feb. 9, 1999, Retrieved From: <<http://www.ncbi.nlm.nih.gov/nuccore/AF… [cited by applicant]
Genbank, “Goose parvovirus, complete genome”, GenBank Accession No. NC001701.1, Aug. 13, 2018, Retrieved From: <<http://www.ncbi.nlm.nih.gov/nuccore/NC001701>>. [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “Human parvovirus B19, complete genome”, GenBank Accession No. NC000883.2, Aug. 13, 2018, Retrieved From: <<http://www.ncbi.nlm.nih.gov/nuccore/NC000883>>. [cited by applicant]
Genbank, “Human Transferrin mRNA, Complete cds”, GenBank Accession No. M12530, Jan. 14, 1995, 2 pages, Retrieved From: <<http://www.ncbi.nlm.nih.gov/nuccore/M12530>>. [cited by applicant]
Genbank, “Minute virus of mice, complete genome”, GenBank Accession No. NC001510.1, Aug. 13, 2018, Retrieved From: <<http://www.ncbi.nlm.nih.gov/nuccore/NC001510>>. [cited by applicant]
Genbank, “Snake parvovirus 1, complete genome”, GenBank Accession No. NC 0096148.1, Aug. 13, 2018, Retrieved From: <<http://www.ncbi.nlm.nih.gov/nuccore/NC006148>>. [cited by applicant]
Genbank, “Synthetic construct hepatocyte-restricted expression cassette”, GenBank Accession No. AY661265, Sep. 29, 2009, Retrieved From: https://www.ncbi.nlm.nih.gov/nuccore/AY661265. [cited by applicant]
Genbank, “Synthetic parvovirus B19, complete genome”, GenBank Accession No. KY940273.1, May 29, 2017, Retrieved From: https://www.ncbi.nlm.nih.gov/nuccore/KY940273.1. [cited by applicant]
Genbank, “Transferrin [Human, Liver, mRNA, 2347 nt]”, GenBank Accession No. S95936, May 7, 1993, 2 pages, Retrieved From: <<http://www.ncbi.nlm.nih.gov/nuccore/S95936>>. [cited by applicant]
Genbank, “Transferrin Precursor [ [cited by applicant]
Genbank, “Von Willebrand Factor Preproprotein [ [cited by applicant]
Gonçalves, M.A. (2005) “Adeno-associated virus: from defective virus to effective vector”, Virol Journal, 2(43). [cited by applicant]
Grimm et al. (1999) “Progress in Adeno-Associated Virus Type 2 Vector Production: Promises and Prospects for Clinical Use”, Hum. Gene Ther., 10(15): 2445-2450. [cited by applicant]
Groth et al. (2000) “A phage integrase directs efficient site-specific integration in human cells”, Proc. Natl. Acad. Sci. USA, 97(11): 5995-6000. [cited by applicant]
Ho et al. (1989) “Site-directed mutagenesis by overlap extension using the polymerase chain reaction,” Elsevier Science Pub. B.V. (Biomed. Div.), Gene, 77: 51-59. [cited by applicant]
Hoeben et al. (1995) “Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region”, Blood, 85(9): 2447-2454. [cited by applicant]
Hoeben et al., “Expression Of Functional Factor VIII In Primary Human Skin Fibroblasts After Retrovirus-Mediated Gene Transfer”, Journal of Biological Chemistry, May 1990, vol. 265, No. 13, pp. 7318-7323. [cited by applicant]
Holt et al. (2008) “Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs,” Protein Engineering, Design and Selection, 21(5):283-288. [cited by applicant]
Horton et al. (1993) “Gene Splicing by Overlap Extension,” Methods in Enzymology, 217 (17): 270-279. [cited by applicant]
Ill et al., (1997) “Optimization Of The Human Factor VIII Complementary DNA Expression Plasmid For Gene Therapy Of Hemophilia A”, Blood Coagulation & Fibrinolysis: An International Journal In Haemostasis And Thrombosis,… [cited by applicant]